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 ABSTRACT 
 The aim of this research was to use probabilistic sen-
sitivity analysis to evaluate the relative importance of 
different components of a model designed to estimate 
the cost of clinical mastitis (CM). A particular focus 
was placed on the importance of pathogen transmis-
sion relative to other factors, such as milk price or 
treatment costs. A stochastic Monte Carlo model was 
developed to simulate a case of CM at the cow level and 
to calculate the associated costs for 5 defined treatment 
protocols. The 5 treatment protocols modeled were 3 d 
of antibiotic intramammary treatment, 5 d of antibiotic 
intramammary treatment, 3 d of intramammary and 
systemic antibiotic treatment, 3 d of intramammary 
and systemic antibiotic treatment plus 1 d of nonste-
roidal antiinflammatory drug treatment, and 5 d of 
intramammary and systemic antibiotic treatment. Uni-
form distributions were used throughout the model to 
enable investigation of the cost of CM over a spectrum 
of clinically realistic scenarios without specifying which 
scenario was more or less likely. A risk of transmission 
parameter distribution, based on literature values, was 
included to model the effect of pathogen transmission 
to uninfected cows, from cows that remained subclini-
cally infected after treatment for CM. Spearman rank 
correlation coefficients were used to evaluate the rela-
tionships between model input values and the estimat-
ed cost of CM. Linear regression models were used to 
explore the effect that changes to specific independent 
variables had on the cost of CM. Risk of transmission 
was found to have the strongest association with the 
cost of CM, followed by bacteriological cure rate, cost of 
culling, and yield loss. Other factors such as milk price, 
cost of labor, and cost of medicines were of minimal 
influence in comparison. The cost of CM was similar for 
all 5 treatment protocols. The results from this study 
suggest that, when seeking to minimize the economic 
impact of CM in dairy herds, great emphasis should be 
placed on the reduction of pathogen transmission from 
cows with CM to uninfected cows. 
 Key words:   mastitis ,  treatment ,  probabilistic sensi-
tivity analysis ,  transmission 
 INTRODUCTION 
 Mastitis remains one of the most common diseases 
of dairy cows and represents a large economic loss to 
the industry as well as a considerable welfare issue to 
the cows affected (Bradley, 2002; Halasa et al., 2007). 
Despite being an infectious disease, concentration is 
often focused on the individual animal with respect to 
treatment, cost, and management. The risk posed to 
the rest of the herd from infected individuals and the 
potential impact of disease transmission on the cost of 
a case of clinical mastitis (CM) is often overlooked. 
 The cost of CM is made up of direct costs (e.g., dis-
carded milk, cost of medicines, and labor) and indirect 
costs (e.g., loss of future production and increased cull-
ing) and varies considerably between farms (Huijps et 
al., 2008). Although the direct costs are more apparent 
to the producer, they are reported to comprise only a 
small proportion of the overall cost of CM compared 
with the less-obvious indirect costs (Kossaibati and Es-
slemont, 2000; Huijps et al., 2008). Several studies have 
taken all of the direct and indirect costs into account 
and have produced average figures of $168 (Bar et al., 
2008), $254 (Huijps et al., 2008), $266 (Kossaibati and 
Esslemont, 2000), and $518 (Hagnestam-Nielsen and 
Ostergaard, 2009) for the cost of a case of CM. Al-
though this information is useful, such average figures 
are difficult to interpret for an individual producer un-
less they happen to have the average farm. Although 
some recent studies have investigated the impact of 
transmission on the overall cost of CM at herd level 
(Halasa et al., 2009; van den Borne et al., 2010; Halasa, 
2012), most studies have not evaluated the impact that 
within-herd transmission may have on the cost of CM 
at the cow level, nor how important this may be rela-
tive to the other factors that make up the overall cost 
of a case of CM. 
 A technique now widely adopted by the human 
healthcare sector for analysis of the cost-effectiveness of 
new and existing treatments is probabilistic sensitivity 
analysis (PSA; Briggs et al., 2002; Brown et al., 2006). 
Indeed, the National Institute for Clinical Excellence 
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(NICE; London, UK) now requires all cost-effectiveness 
analyses submitted to the institute to use PSA (Clax-
ton et al., 2005). The main feature of this technique is 
that all input parameters in a cost-effectiveness model 
are specified as full probability distributions (proba-
bilistic), rather than point estimates (deterministic), 
to represent the uncertainty surrounding their values. 
This parameter uncertainty can then be propagated 
through the cost-effectiveness model so that imprecision 
in model outputs is transparent (Briggs et al., 2002). 
For example, rather than using a point estimate for the 
probability of clinical cure after the treatment of CM 
of, say, 60%, we might choose a probability distribution 
covering the range 40 to 80% instead, accepting that we 
don’t know the precise figure, but being fairly confident 
that it lies somewhere within this range. The relative 
importance of different model parameter values on the 
outcome of interest can then be evaluated irrespective 
of model complexity. This form of analysis has wide-
spread acceptance within the human healthcare sector, 
but the authors could find only 1 example of its use in 
the veterinary literature (Detilleux, 2004).
The purpose of this research was to use PSA to eval-
uate the relative importance of different components 
of a model designed to estimate the cost of CM. The 
model included the potential for pathogen transmis-
sion between cows and was an extension of a previously 
described model structure (Steeneveld et al., 2011). A 
particular aim was to assess the importance of the rate 
of transmission relative to other factors, such as milk 
price or the cost of therapeutic agents.
MATERIALS AND METHODS
Model Structure
A stochastic Monte Carlo model was developed us-
ing WinBUGS 1.4.3 software (Lunn et al., 2000). This 
was used to simulate an initial case of CM (CM1) at 
the cow level and to calculate the associated costs si-
multaneously for 5 treatment protocols as defined by 
Steeneveld et al. (2011). The 5 protocols used were 3 
d of antibiotic intramammary treatment (treatment 
1), 5 d of antibiotic intramammary treatment (treat-
ment 2), 3 d of intramammary and systemic antibiotic 
treatment (treatment 3), 3 d of intramammary and 
systemic antibiotic treatment plus 1 d of nonsteroidal 
antiinflammatory drug treatment (treatment 4), and 
5 d of intramammary and systemic antibiotic treat-
ment (treatment 5). The initial probability that the 
cow was cured bacteriologically was defined by a prob-
ability distribution based on the maximal cure rates 
given by Steeneveld et al. (2011), but rather than being 
pathogen specific (e.g., Staphylococcus aureus, Strepto-
coccus dysgalactiae/uberis, or Escherichia coli), a single 
distribution was used providing coverage of cure rates 
encompassing those for all of the pathogens modeled by 
Steeneveld et al. (2011). For example, for treatment 1 
(3 d of intramammary treatment), the bacteriological 
cure rates given ranged from 0.80 for E. coli infections 
down to 0.40 for Staph. aureus infections, so the uniform 
distribution 0.40 to 0.80 was used for all treatment-1 
cases. After an initial treatment, 3 outcomes were pos-
sible: complete cure (bacteriological plus clinical cure), 
clinical cure (with no bacteriological cure), or no cure 
(no clinical and no bacteriological cure), with probabili-
ties based upon Steeneveld et al. (2011; Table 1). The 
probability that a case was cured bacteriologically was 
assumed to be further influenced by whether the cow 
was systemically ill, the SCC at the time of treatment, 
the DIM at the time of treatment, parity, and whether 
it was a repeat case or not (Steeneveld et al., 2011; 
Table 1). The cows that failed to cure bacteriologically 
were deemed to have an 80% chance of curing clinically 
(Steeneveld et al., 2011).
The model structure was adapted from the model 
described by Steeneveld et al. (2011; Figure 1), which 
models the sequelae following a case of CM within a 
single lactation, with the addition of a risk of trans-
mission from cows that cured clinically but not bacte-
riologically. Cases that completely cured could either 
go on to finish the lactation or be culled within the 
remainder of the lactation. The probability of being 
culled was increased if the cow was systemically ill at 
the time of treatment. The cows that cured clinically 
but not bacteriologically could go on to finish the cur-
rent lactation, be culled, or have a clinical recurrence 
of the original case (CM2). If a cow did not cure, it 
would receive a repeat course of the initial treatment 
protocol, resulting in the same 3 possible outcomes as 
previously outlined. Cows that failed to cure after a 
repeated course could either die or have the quarter 
dried off. If a quarter was dried off, the cow could then 
go on to finish the lactation at a reduced level of milk 
production, or be culled (Table 2). The same sequence 
of events was modeled for CM2, but after CM3 the 
options became narrower. The cows that cured com-
pletely after CM3 could either end the lactation or be 
culled. The clinical (but not bacteriological) cures and 
the “no cures” were culled as was the case in the model 
described by Steeneveld et al. (2011). The probabilities 
of a cow being culled varied according to whether the 
case was a first, second, or third case. The distributions 
used in the model are shown in Tables 1 and 2. Follow-
ing each treatment for CM, the probability of a cow 
curing bacteriologically was selected from the specified 
distribution and of those cows that failed to cure, 80% 
were assumed to cure clinically but not bacteriologi-
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cally as described by Steeneveld et al. (2011) and the 
remaining cows were assumed to fail to cure.
A risk of transmission was included from cows that 
cured clinically but not bacteriologically (those that 
did not cure clinically received another treatment and 
were deemed to be not at risk of transmission at this 
point). The probability that a cow transmitted infec-
tion to a herd mate (Table 2) was taken from van den 
Borne et al. (2010), who reported estimated transmis-
sion rates over a 14-d period for infections caused by 
Staph. aureus, Strep. uberis/dysgalactiae and E. coli. 
A uniform distribution was specified [range 0.002 to 
0.25, encompassing the estimates of van den Borne et 
al. (2010)], from which a value was selected at random 
at each iteration and used for each period of risk there-
after. The total period of transmission risk modeled 
was limited to 12 wk, split into 14-d intervals for CM1 
and CM2. Therefore, the risk of transmission had a 
wide distribution to reflect and encompass all types of 
pathogens and strains. Thus, using 1 distribution, we 
could evaluate differences between a very-low-transmis-
sion pathogen and a very-high-transmission pathogen.
The susceptible population was taken as the whole 
herd (99 cows) at the start of the transmission period 
and was reduced according to the number of cows that 
became infected after each 14-d period during the sub-
sequent 12 wk. Cow parities and stage of lactation of 
the susceptible population were not modeled separately; 
thus, for simplicity, all susceptible cows we assumed to 
have an equal probability of acquiring an infection. All 
cows that were infected at the end of the previous 14-d 
period were eligible to transmit infection during the 
next 14-d period according to the defined probability 
distribution (Table 2). For example, if the cow treated 
at CM1 remained subclinically infected after treatment, 
it could transmit the infection to another cow in the 
herd during the following 14-d period. At the start of 
the subsequent 14-d period, 2 infectious cows could now 
be able to transmit infection to another 2 cows during 
the next 14-d period. If 3 cows had become infected 
in addition to the original case, then the susceptible 
population would be reduced to 96 cows. The total 
number of infections accrued from CM1 and CM2 were 
combined and the costs of subsequent cases of CM were 
estimated by multiplying the cost from the original case 
(CM1) by the number of extra cases of CM caused by 
transmission of the original infection (thus assuming 
the same milk price, culling values, and so on, as for the 
initial case). A total cost of CM was derived by adding 
the costs from the original and secondary cases, follow-
ing transmission. For example, if the cost of a case of 
CM was calculated to be $200 (excluding transmission) 
but the cow infected 2 herd mates, then the total cost 
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(including transmission) would be calculated as $600 
($200 × 3).
Model Input Parameters
The model was parameterized (i.e., the model inputs 
selected) with distributions taken from the existing lit-
erature and from current commercial data, and where 
no other information was available, on transparent as-
sumptions made by the dairy health group, University 
of Nottingham (Sutton Bonington, UK; Tables 1 and 
2). The purpose was to enable exploration of the rela-
tionship between each model parameter and the overall 
cost-benefit of each treatment protocol over a wide 
range of possible scenarios. Although not a requirement 
of PSA, uniform distributions were used throughout 
the model to enable evaluation of the cost of CM over 
a spectrum of different scenarios without specifying 
which scenarios were more or less likely, thereby mini-
mizing assumptions. This was not intended to represent 
the true distribution of the input parameters (which 
are generally unknown), but simply to allow investiga-
tion over the whole of a realistic range of equally likely 
parameter values and thus treatment scenarios. After a 
large number of model iterations (4,000 per treatment 
protocol), all combinations of treatment scenarios and 
other input parameters were effectively investigated so 
that dependencies could be evaluated.
Where possible, distribution ranges were based on 
values from current literature. Where a point estimate 
was identified in the literature, a uniform distribution 
centered on that point was used, to allow sensitivity 
analysis of realistic values around this point estimate. 
For example, the increase in probability of a cow be-
ing culled within the remainder of lactation when sys-
temically ill was estimated to be 0.10 (Steeneveld et 
al., 2011). In our model, a uniform distribution of 0.05 
to 0.15 was used to evaluate this parameter over an 
enlarged but specified range. The distributions used for 
input parameters are shown in Tables 1 and 2, along 
Figure 1. Schematic representation of the treatment model. Complete cure = bacteriological and clinical cure; clinical cure = no bacterio-
logical cure but clinical cure; no cure = no bacteriological or clinical cure; cull = culled sometime within the remainder of the current lactation; 
extended treatment = a repeat of the same treatment that the case received initially; RT = risk of transmission; CM1 = initial case of clinical 
mastitis; CM2 = first clinical flare-up; CM3 = second clinical flare-up.
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Table 2. Probability distributions applicable to all 5 antimicrobial clinical mastitis (CM) treatment protocols 
Input parameter
Lower and upper  
limits of uniform  
distribution Source
Change in the probability of bacteriological cure1 Based on Steeneveld et al. (2011)
 Parity ≥2 −0.15, −0.05
 DIM ≥60 −0.15, −0.05
 Cow is systemically ill −0.25, −0.15
 SCC 200,000 to 500,000 cells/mL at most recent recording −0.15, −0.05
 SCC >500,000 cells/mL at most recent recording −0.25, −0.15
 Repeated case (>first case in current lactation) −0.25, −0.15
Probability of being culled for bacteriologically noncured cases Based on Steeneveld et al. (2011)
 Initial case 0, 0.32
 Following first flare-up (CM2) 0.04, 0.36
Probability of being culled for completely cured cases Based on Steeneveld et al. (2011)
 Initial case 0.04, 0.06
 Following first flare-up (CM2) 0.10, 0.20
 Following second flare-up (CM3) 0.20, 0.30
Probability of death for nonclinically cured cases 0.04, 0.06 Based on Steeneveld et al. (2011)
Probability of drying-off quarter for nonclinically cured cases 0.94, 0.96 Based on Steeneveld et al. (2011)
Probability of being culled for cows with dried-off quarters 0.27, 0.39 Based on Steeneveld et al. (2011)
Increase in all culling probabilities when cow is systemically ill 0.05, 0.15 Based on Steeneveld et al. (2011)
Probability of clinical flare-up for bacteriologically noncured cases 0.05, 0.12 Based on Steeneveld et al. (2011)
Probability of transmission after CM1 and CM2 0.002, 0.25 van den Borne et al. (2010)
Proportional yield loss Based on Steeneveld et al. (2011)
 Case in first or second month of lactation 0.07, 0.09
 Case between mo 3 and 6 0.03, 0.08
 Case after mo 6 0, 0.04
 Parity ≥2 0, 0.02
305-d yield (kg) 7,000, 10,000 Authors’ expertise
Daily milk discard (kg) 5.00, 50.00 Authors’ expertise
Value of discarded milk ($/kg) 0.35, 0.41 DairyCo (2012a)
Cost of milk production ($/kg) 0.05, 0.15 Based on Huijps et al. (2008)
Cost of labor ($/h) 1.52, 24.07 Based on Huijps et al. (2008)
Cost of cull ($) 182, 1,092 Based on Huijps et al. (2008) and Kossaibati and Esslemont (2000)
Cost of death ($) 1,820, 3,033 DairyCo (2012b)
1The value selected from this distribution was subtracted from the value selected from the bacteriological cure distribution.
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with the source or basis for the choice of each distribu-
tion.
Economic parameter distributions included the cost 
of drugs (Table 1), labor, milk withdrawal and loss 
of milk production, culling, and death (Table 2). The 
original calculations were made in British pounds (£) 
and converted to US dollars ($) using the exchange 
rate of 1.5170 $/£ (http://www.xe.com/currency 
converter/; accessed March 5, 2013). The cost of labor 
is subject to large variation quoted in the literature. 
For this reason, a wide distribution was assigned to the 
hourly cost of labor, with the upper limit taken from 
Huijps et al. (2008). The total time taken to treat each 
case of CM was assigned a distribution centered on the 
figures given by Steeneveld et al. (2011), surrounded by 
an additional variation of ±10 min. The total cost of 
labor was the product of the hourly rate and the total 
treatment time.
The length of milk withdrawal after CM was defined 
by a distribution based on the commonly used medi-
cines in the United Kingdom and the amount of milk 
being discarded each day was taken from a plausible 
milk yield distribution (Table 1). The distribution de-
fined for milk price was taken from DairyCo (2012a) 
and based on the average UK milk price over the last 
12 mo (range: lowest price to highest price). The cost of 
milk production was based on Huijps et al. (2008) and 
assigned a uniform distribution to reflect the variability 
in the figure (Table 2).
The calculation of total yield loss following a case 
of CM was based on the herd 305-d yield, the parity 
of the animal, and the stage of lactation in which the 
infection occurred (Table 2). The distributions govern-
ing the percentage of total loss in 305-d milk yield were 
based on Hagnestam et al. (2007). The proportion of 
cases occurring at each stage postpartum and the pro-
portion of cases affecting multiparous cows versus pri-
miparous cows was governed by distributions based on 
Steeneveld et al. (2011; Table 2). The cost associated 
with the total loss in milk yield was calculated accord-
ing to the total loss in earnings (i.e., the quantity of 
milk multiplied by the milk price) minus the savings 
made in feed costs (i.e., the quantity of milk loss mul-
tiplied by the cost of production). All distributions are 
provided in Table 2.
The cost of culling a cow within the remainder of the 
current lactation was taken from a uniform distribution 
based on Huijps et al. (2008) and Kossaibati and Es-
slemont (2000), which included the slaughter value and 
replacement costs, with an appropriate range added to 
reflect the variability of this parameter (Table 2). The 
cost of the death of an individual was based on current 
UK average sales prices for freshly calved cows and 
heifers (DairyCo, 2012b), which would be required to 
replace the dead cow in addition to the cost of carcass 
disposal (Table 2).
Model Simulation
The model was used to simulate 4,000 cases of CM1 
for each treatment protocol. At each iteration, all model 
input parameter values for that iteration were stored 
along with the calculated cost of a CM1 case; this data 
was then used for analysis.
At each model iteration, a value for each input pa-
rameter was drawn from the probability distribution 
for that input parameter, independent of other param-
eter values selected, and the model used to calculate a 
cost of CM based on those input values. At the next 
iteration, a new set of parameter values were selected 
at random and used to calculate a cost of CM. This 
process was repeated 4,000 times for each of the 5 treat-
ment protocols and the impact of each parameter on 
the cost of CM was evaluated.
Data Analysis
Spearman rank correlation coefficients were calcu-
lated to explore the univariate associations between 
model input parameters and the cost of CM (Table 3). 
The strength of the relationship was evaluated using 
the Spearman rank rho (ρ) value.
Conventional first-order multiple linear regression 
models were used to explore the relationships between 
model inputs (Tables 1 and 2) and the cost of CM for 
each of the treatment protocols (one model was con-
structed for each treatment protocol). A natural loga-
rithmic transformation was required for the outcome 
variable (cost of CM) to give normality and homosce-
dasticity of the residuals. Model fit was assessed using 
a visual assessment of residuals and a quantile-quantile 
plot to evaluate normality. The influence of any outly-
ing residuals was assessed using the Cook’s D value. 
Predictor variables were selected by backward stepwise 
selection and variable coefficients that were significantly 
different from zero (P < 0.05) were retained in the final 
model. All analysis was performed in R version 2.15.0 
software (R Development Core Team, 2012).
The relative importance of the independent variables 
(model input parameters) on the cost of CM was as-
sessed for each of the 5 treatment protocols by removing 
the variable from the model and observing the differ-
ence in the resulting coefficient of determination value. 
This difference was then expressed as a proportion of 
the coefficient of determination value of the complete 
model.
The final regression models were used to make pre-
dictions based on different cow and farm scenarios and 
Journal of Dairy Science Vol. 96 No. 10, 2013
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to explore the predicted effect these would have on the 
overall cost of CM. This was undertaken by altering 
the value of each of the independent variables in the 
model in turn from their median value to the 97.5th 
percentile while keeping all other variables constant at 
their median value and recording the resulting change 
in the model output (cost of CM) as a percentage. This 
was performed using Microsoft Excel 2010 software 
(Microsoft Corp., Redmond, WA).
RESULTS
Data Analysis
The Spearman rank correlation coefficients are pre-
sented in Table 3. The cost of CM was most closely 
associated with the risk of transmission of infection 
for all 5 treatment protocols. This was followed by the 
bacterial cure rate, the cost of a cull, total loss in yield, 
and the presence or absence of systemic illness.
The regression model fit was good for each of the 
5 treatment protocols and outliers had no significant 
influence on the model output. The results of the 
regression analysis are illustrated in Figure 2. Trans-
mission of infection had the greatest influence on the 
overall cost of CM for all 5 treatment protocols, and 
the number of cows infected as a result of CM1 ranged 
from 0 to 3 over the total period of risk (Table 4). This 
was followed by occurrence of systemic illness, cost of 
a cull and total yield loss during the remainder of the 
lactation. In total, 13 independent variables were re-
tained in the final models. The relative importance of 
variables differed only slightly between the 5 treatment 
protocols; the general trends were similar throughout.
The most influential financial input was the cost of 
a cull, which accounted for around 10% of the variance 
in the total cost of CM, followed by the cost of milk 
production, milk price, and cost of labor. The cost of 
drugs was not found to be a significant predictor and 
was excluded from the final models. The relationship 
between the most important independent variables and 
the cost of CM are displayed in Figure 3.
Scenarios
The regression models were used to explore the ef-
fect that changes to specific independent variables had 
on the overall cost of CM and the results from treat-
ment 1 are displayed in Figure 4. An increase in the 
rate of transmission from 0.13 to 0.25 new cases/14 d 
would increase the predicted cost of CM by up to 60%, 
whereas doubling the cost of labor from around $12.89 
Table 3. Spearman rank correlation coefficients measuring the statistical dependence between the main 
specified variables and the total cost of clinical mastitis 
Item
Antimicrobial treatment regimen
Treatment 11 Treatment 22 Treatment 33 Treatment 44 Treatment 55
Transmission 0.70 0.68 0.71 0.70 0.64
Bacteriological cure rate6 −0.24 −0.10 −0.07 −0.13 −0.09
Cost of cull 0.23 0.24 0.24 0.24 0.25
Total yield loss 0.23 0.23 0.22 0.22 0.23
Not systemically ill −0.23 −0.25 −0.25 −0.25 −0.27
Heifer −0.15 −0.16 −0.16 −0.17 −0.17
Not a repeat case −0.12 −0.14 −0.13 −0.14 −0.15
Milk price 0.10 0.11 0.11 0.11 0.11
SCC >500,000 cells/mL7 0.10 0.09 0.09 0.08 0.09
Cost of milk production −0.10 −0.10 −0.10 −0.11 −0.11
Less than 60 DIM8 −0.09 −0.10 −0.10 −0.11 −0.11
Milk withdrawal9 0.09 0.07 0.07 0.12 0.07
Cost of labor 0.02 0.04 0.02 0.02 0.04
Cost of drugs 0.02 0.00 0.02 0.00 0.01
1Three days of antibiotic intramammary treatment.
2Five days of antibiotic intramammary treatment.
3Three days of intramammary and systemic antibiotic treatment.
4Three days of intramammary and systemic antibiotic treatment plus 1 d of nonsteroidal antiinflammatory 
drug treatment.
5Five days of intramammary and systemic antibiotic treatment.
6Baseline bacteriological cure rate before further influence of systemic illness, parity, DIM, SCC, and case 
number.
7Somatic cell count at the time of clinical mastitis.
8Less than 60 DIM at the time of clinical mastitis case.
9Milk withdrawal during antibiotic treatment.
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Figure 2. Bar charts depicting the proportion of variance in the total cost of clinical mastitis (CM) accounted for by each variable in the 
regression model for each of the treatment protocols. Treatment 1 = 3 d of antibiotic intramammary treatment; treatment 2 = 5 d of antibiotic 
intramammary treatment; treatment 3 = 3 d of intramammary and systemic antibiotic treatment; treatment 4 = 3 d of intramammary and 
systemic antibiotic treatment plus 1 d of nonsteroidal antiinflammatory drug treatment; treatment 5 = 5 d of intramammary and systemic 
antibiotic treatment. Milk discard = milk discarded during treatment.
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to $23.51/h would only be expected to increase the cost 
of mastitis by around 5%. Systemic illness had a large 
effect on the total cost of CM (40%), if present due to 
the depressing effect this had upon the probability of 
bacteriological cure. The cost of a cull had a moderate 
effect on the cost of CM, with an increase from $637 to 
$1,065 resulting in a 15 to 20% increase in the overall 
cost.
DISCUSSION
The results suggest that the risk of transmission of 
infection has the greatest influence on the cost of a 
case of CM and this appeared to be by a wide margin. 
Indeed, a relatively small increase in the rate of trans-
mission was associated with a large increase in cost 
(Figure 4) and this is consistent with a study by Halasa 
(2012) that reported that the total annual net cost of 
IMI was highly sensitive to the transmission rate of 
Staph. aureus.
The potential for transmission of IMI between cows is 
well established (Barkema et al., 2009) and yet despite 
this, relatively few studies exist that seek to quantify 
this phenomenon (Lam et al., 1996; Zadoks et al., 2001, 
2002). The transmission data from these studies has 
been used to inform some economic (Swinkels et al., 
2005a,b; van den Borne et al., 2010) and epidemiologi-
cal studies (Barlow et al., 2009), but these were all set 
in the context of treatment of subclinical mastitis. One 
study that did include transmission in a discrete-event 
model investigating the cost of pathogen-specific IMI in 
a herd of 100 dairy cows, found that the total net cost 
was most sensitive to the transmission rate parameter 
(Halasa et al., 2009). A limitation of previous research 
on pathogen-specific transmission rates is that the rate 
is likely to vary considerably between different strains 
of the same pathogen and the advantage of using PSA 
is that a single distribution could be used to encompass 
many different plausible rates (based on the literature) 
and the importance of this parameter could be investi-
gated without the need to make assumptions as to how 
a particular pathogen may or may not behave. There-
fore, the variation in the transmission rate parameter 
in this study effectively takes into account known varia-
tion in pathogen and strain of bacteria. Although the 
use of uniform distributions means that no assessment 
is made as to which scenario is more or less likely and, 
therefore, which transmission value is most common, 
their use does mean that the relative importance of 
the different transmission values affecting the cost of 
CM can be robustly assessed across a wide range of 
plausible situations.
In the model described in this study, cows that cured 
bacteriologically following treatment could go on to T
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Figure 3. Series of high-density scatterplots [relatively darker shading means relatively greater point density (i.e., occurred more frequently)] 
demonstrating the relationship between a predictor variable and the total cost of clinical mastitis (CM) for treatment 1 (3 d of intramammary 
antibiotic). Transmission refers to the risk of cows becoming infected due to the original case over a 12-wk period. Bacteriological cure rate refers 
to the baseline bacteriological cure rate, without accounting for systemic illness, parity, DIM, SCC, or repeat case. 1Binary outcome; therefore, 
2 possible outcomes exist. The cluster of data points on the left-hand side of the chart represent the cost of mastitis, given the presence of the 
predictor variable and the cluster of points on the right-hand side of the chart indicates the cost of mastitis, given the absence of the predictor 
variable. The x-axis value represents the effect on the probability of bacteriological cure.
Journal of Dairy Science Vol. 96 No. 10, 2013
TRANSMISSION AND THE COST OF CLINICAL MASTITIS 6311
either finish the lactation or be culled and at no point 
could they transmit infection to other cows. Cows that 
remained subclinically infected could either end the lac-
tation, be culled, or experience a repeat case of CM and 
during this time they were considered eligible to trans-
mit infection, whichever route they followed. Although 
this may represent a simplification of the biological real-
ity, it is probably these subclinically infected cows that 
represent the major reservoir of contagious pathogens 
and the way in which those cows are managed could 
have a significant effect on the degree of between-cow 
transmission and hence the cost of mastitis.
Transmission of contagious mastitis pathogens 
mainly occurs during milking (Fox and Gay, 1993) and 
measures aimed at reducing transmission therefore 
tend to focus on the milking process, the management 
of the cows at milking, and the milking machine itself. 
A recent systematic review of the effect of udder health 
management practices on herd SCC highlighted the 
importance of wearing gloves while milking, the use 
of (well-adjusted) automatic cluster removal, applica-
tion of postmilking teat disinfection, milking cows with 
CM or a high SCC last, and the annual inspection of 
the milking machine (Dufour et al., 2011). Although 
such studies measuring association are not evidence of 
causality, they do highlight practices that are likely to 
help minimize the transmission of IMI and appear to 
be relatively well adopted by dairy farmers (Rodrigues 
et al., 2005; Olde Riekerink et al., 2010). The segrega-
tion of infected cows represents a challenge for many 
producers, both logistically and diagnostically, because 
creating an additional group may add to space and time 
pressures and a certain amount of expenditure and ef-
fort will be required to diagnose infected cows. Despite 
this, it would seem logical that keeping infectious cows 
separate to susceptible individuals should reduce spread 
and evidence exists to support this in the literature 
(Wilson et al., 1995; Middleton et al., 2001; Zecconi et 
al., 2003). A possible alternative to segregation is back-
flushing the milking unit to prevent uninfected cows 
from being exposed to contaminated milking units from 
infectious cows (Keefe, 2012) and some evidence exists 
of its efficacy (Hogan et al., 1984; Smith et al., 1985). 
Although this may represent a significant investment to 
Figure 4. Tornado plot to demonstrate the predicted effect of a change in the predictor variable from the 50th to the 97.5th percentile on 
the total cost of clinical mastitis (CM) when all of the others remain constant in the regression model. The results for treatment 1 only are 
displayed, as results were similar for all 5 treatment protocols. Treatment 1 = 3 d of intramammary antibiotic treatment. Transmission refers 
to the risk of transmission over a 14-d period.
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install, it may offer a pragmatic solution on farms for 
which in-parlor transmission appears to be a problem 
but for whom segregation is not a viable option.
The role of the milking machine in transmission of 
mastitis should not be ignored despite advancements 
aimed at reducing its involvement. It is considered 
to account for up to 20% of new IMI in some herds, 
although it is probably closer to around 10% in most 
average herds, provided the machine is appropriately 
configured (Mein, 2012). To minimize the risk of patho-
gen spread via the milking machine, it should be in-
spected at least annually (Dufour et al., 2011), which is 
especially pertinent given that 61% of UK parlors failed 
their annual test in one study (Berry et al., 2005).
The measuring and hence monitoring of transmission 
remains challenging at present and has typically been 
estimated using SCC trends, CM incidence data, and 
bacteriology (Barkema et al., 2009). Molecular epide-
miological techniques (Zadoks and Schukken, 2006) are 
required to measure how much transmission is occur-
ring and these are not currently widely available in the 
commercial setting. This is, however, likely to change 
with advances in technology and, thus, the ability to 
accurately quantify and monitor the degree of trans-
mission in dairy herds should improve.
After transmission, the most important factors 
influencing the cost of CM were bacteriological cure 
rate, cost of a cull, and loss in yield. This is consistent 
with other studies (Huijps et al., 2008; Halasa, 2012; 
Heikkilä et al., 2012). van den Borne et al. (2010) also 
reported that the cost of mastitis was sensitive to the 
bacteriological cure rate, with higher cure rates result-
ing in reduced costs due to mastitis when modeling 
the effect of lactational treatment of subclinical IMI. 
Barlow et al. (2009) found that increasing the cure 
rate of subclinical IMI was beneficial at some levels of 
transmission but when transmission was high, it could 
be counterproductive, as it resulted in more uninfected 
cows (quarters) being available to be reinfected.
In the model used in this study, bacteriological cure 
rate was structured to be affected by cow factors such 
as parity, SCC at the time of infection, systemic illness, 
case number, and DIM, as described by Steeneveld et 
al. (2011). However, we used probability distributions 
rather than point estimates for the cow factors and this 
resulted in a highly variable set of possible values for 
bacteriological cure rate, which we believe reflects real 
potential situations. As expected, factors that affect the 
probability of bacteriological cure had an important 
influence on the cost of CM, although more research 
would be useful to determine the real degree of varia-
tion in these values in the field and the reasons for such 
variation. The other parameters in the model, such as 
milk price, length of milk withdrawal, and the cost of 
labor, proved to be of lesser significance to the cost of 
CM. Interestingly, the cost of medicines was found to 
have little bearing on the overall cost of a case of CM 
(Table 3).
In this study, the probability distributions used for 
the bacteriological cure rate reflected an increased 
chance of cure for the more aggressive treatment proto-
cols overall (Table 1). A large degree of overlap existed 
in the bacteriological cure rates for the different treat-
ment protocols and the same was true of the model 
outputs (Table 4), which showed that the overall cost 
of CM was very similar despite the treatment protocol 
selected. The median total costs (Table 4) were higher 
than most figures quoted in the literature, as they 
included the costs incurred by any transmission that 
happened as a result of the case of CM, which most 
other figures do not. So, rather than representing the 
cost of a case of CM, it may be more appropriate to 
think of the values for total cost in Table 4 in terms of 
the room for investment in preventing a case of CM. 
The median costs, without taking into account trans-
mission, were higher than the equivalent figures quoted 
by Steeneveld et al. (2011) but these do not necessar-
ily represent an average cost for mastitis because with 
the use of uniform distributions in the current study, 
the aim was to fully explore causes of variation in cost 
rather than averages. Treatment 1 (3 d of intramam-
mary antibiotic) resulted in the lowest median cost, as 
was found by Steeneveld et al. (2011), but also had the 
broadest range, which is intuitive, given the increased 
risk of transmission, subclinical infection, and culling 
associated with a reduced bacteriological cure rate. 
Therefore, and importantly, the treatment protocol 
selected appears to be much less important than other 
factors such as transmission. Steeneveld et al. (2011) 
hypothesized that the inclusion of transmission would 
favor the intensive antibiotic treatment regimens and 
some evidence existed to support this hypothesis in 
the results from our model, with the most aggressive 
treatment protocol (treatment 5) being less highly cor-
related to the rate of transmission than the other pro-
tocols (Table 3) and resulting in fewer cows becoming 
infected due to transmission (Table 4). The increased 
bacteriological cure rate associated with treatment 5 
was based on expert opinion rather than specific stud-
ies, but if intensive antibiotic treatment protocols were 
indeed found to reduce transmission, then our model 
would indicate that the potential economic benefits 
could be far greater than simply those associated with 
the individual cow. More data on expected cure rates 
would be needed to improve our understanding of this 
aspect.
The use of modeling in economic evaluations is now 
widespread in the healthcare sector, as it enables the 
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investigation of the likely range of outcomes (cost-
effectiveness) under different assumptions, even when 
the exact magnitude of key variables is unknown (Bux-
ton et al., 1997). Probabilistic sensitivity analysis has 
become the state-of-the-art method for determining 
the uncertainty in the outcomes of cost-effectiveness 
studies because of the uncertainty in input parameters 
(Boshuizen and van Baal, 2009). Concerns exist that 
the use of deterministic or univariate sensitivity analysis 
may underestimate overall uncertainty (Briggs, 2000) 
and become difficult to interpret with large numbers 
of parameters, especially if any are correlated (Clax-
ton et al., 2005). Such limitations with other forms of 
sensitivity analysis have led to the development of PSA 
based on Monte Carlo simulation methods (O’Brien et 
al., 1994). Probabilistic sensitivity analysis permits the 
analyst to examine the effect of joint uncertainty in the 
variables of an analysis without resorting to the wide 
range of results generated by extreme scenario analysis 
(Briggs and Gray, 1999). Parameter correlation is prop-
agated automatically, providing meaningful sensitivity 
analysis, regardless of parameter correlation (Ades et 
al., 2006). Given that the literature is often quite sparse 
concerning many of the model inputs required, assump-
tions are usually necessary for this kind of model and 
this can result in unreliable conclusions being drawn if 
this uncertainty is not properly investigated. By using 
PSA, we can reflect the level of uncertainty by defining 
the parameters as distributions that are specified and 
transparent. The distributions used do require a degree 
of judgment and this has to be carried out in an open 
and transparent way and based on current literature 
where possible.
Our model calculated transmission over a limited pe-
riod of 12 wk, a constraint primarily due to increasing 
model complexity. The amount of time that a cow re-
mains infective following an IMI is dependent on many 
different factors and, hence, extremely variable. The 
duration of non-agalactiae streptococcal infections may 
range from 1 d to 1 lactation (Todhunter et al., 1995; 
Zadoks et al., 2003), with a median of 42 d (Zadoks 
et al., 2003). For Staph. aureus, the average length of 
infectivity was found to be 115 d for herds practicing 
postmilking teat disinfection (Lam et al., 1997). Given 
these findings, the 12-wk period that we used could 
have resulted in an underestimation of the effect of 
transmission.
CONCLUSIONS
The risk of transmission was found to be by far the 
most influential parameter in a PSA investigating the 
factors affecting the cost of CM at the individual cow 
level. This was followed by bacteriological cure rate, 
cost of culling, and loss of yield. The results from this 
study suggest that more emphasis should be placed on 
the reduction in the risk of transmission in dairy herds 
when seeking to minimize the economic impact of CM.
REFERENCES
Ades, A. E., K. Claxton, and M. Sculpher. 2006. Evidence synthe-
sis, parameter correlation and probabilistic sensitivity analysis. 
Health Econ.  15:373–381.
Bar, D., L. W. Tauer, G. Bennett, R. N. González, J. A. Hertl, Y. H. 
Schukken, H. F. Schulte, F. L. Welcome, and Y. T. Gröhn. 2008. 
The cost of generic clinical mastitis in dairy cows as estimated by 
using dynamic programming.  J. Dairy Sci.  91:2205–2214.
Barkema, H. W., M. J. Green, A. J. Bradley, and R. N. Zadoks. 2009. 
Invited review: The role of contagious disease in udder health.  J. 
Dairy Sci.  92:4717–4729.
Barlow, J. W., L. J. White, R. N. Zadoks, and Y. H. Schukken. 2009. 
A mathematical model demonstrating indirect and overall effects 
of lactation therapy targeting subclinical mastitis in dairy herds. 
Prev. Vet. Med.  90:31–42.
Berry, E. A., M. Scrivens, and J. E. Hillerton. 2005. Milking machine 
test survey of UK herds.  Vet. Rec.  157:147–148.
Boshuizen, H. C., and P. H. M. van Baal. 2009. Probabilistic sensitiv-
ity analysis: Be a Bayesian.  Value Health  12:1210–1214.
Bradley, A. J. 2002. Bovine mastitis: An evolving disease.  Vet. J. 
164:116–128.
Briggs, A. H. 2000. Handling uncertainty in cost-effectiveness models. 
Pharmacoeconomics  17:479–500.
Briggs, A. H., R. Goeree, G. Blackhouse, and B. J. O’Brien. 2002. 
Probabilistic analysis of cost-effectiveness models: Choosing be-
tween treatment strategies for gastroesophageal reflux disease. 
Med. Decis. Making  22:290–308.
Briggs, A. H., and A. M. Gray. 1999. Handling uncertainty when per-
forming economic evaluations of health care interventions: A sys-
tematic review with special reference to the variance and distribu-
tional form of cost data.  Health Technol. Assess.  3.
Brown, J., N. J. Welton, C. Bankhead, S. H. Richards, L. Roberts, 
C. Tydeman, and T. J. Peters. 2006. A Bayesian approach to 
analysing the cost-effectiveness of two primary care interventions 
aimed at improving attendance for breast screening.  Health Econ. 
15:435–445.
Buxton, M. J., M. F. Drummond, B. A. Van Hout, R. L. Prince, T. 
A. Sheldon, T. Szucs, and M. Vray. 1997. Modelling in economic 
evaluation: An unavoidable fact of life.  Health Econ.  6:217–227.
Claxton, K., M. Sculpher, C. McCabe, A. Briggs, R. Akehurst, M. 
Buxton, J. Brazier, and T. O’Hagan. 2005. Probabilistic sensitivity 
analysis for NICE technology assessment: Not an optional extra. 
Health Econ.  14:339–347.
DairyCo. 2012a. GB farmgate milk prices. Accessed Feb. 12, 
2012. http://www.dairyco.org.uk/market-information/milk-prices-
contracts/farmgate-prices/uk,-gb-and-ni-farmgate-prices/.
DairyCo. 2012b.GB cow and heifer prices. Accessed Feb. 12, 2012. 
http://www.dairyco.org.uk/market-information/farm-expenses/
cow-heifer-prices/gb-cow-heifer-prices/.
Detilleux, J. C. 2004. Javelin diagrams: Applications in veterinary 
medical decision analysis.  Vet. Res.  35:617–624.
Dufour, S., A. Fréchette, H. W. Barkema, A. Mussell, and D. T. Scholl. 
2011. Invited review: Effect of udder health management practices 
on herd somatic cell count.  J. Dairy Sci.  94:563–579.
Fox, L. K., and J. M. Gay. 1993. Contagious mastitis.  Vet. Clin. North 
Am. Food Anim. Pract.  9:475–487.
Hagnestam, C., U. Emanuelson, and B. Berglund. 2007. Yield losses 
associated with clinical mastitis occurring in different weeks of 
lactation.  J. Dairy Sci.  90:2260–2270.
Hagnestam-Nielsen, C., and S. Østergaard. 2009. Economic impact of 
clinical mastitis in a dairy herd assessed by stochastic simulation 
using different methods to model yield losses.  Animal  3:315–328.
6314 DOWN ET AL.
Journal of Dairy Science Vol. 96 No. 10, 2013
Halasa, T. 2012. Bioeconomic modeling of intervention against clinical 
mastitis caused by contagious pathogens.  J. Dairy Sci.  95:5740–
5749.
Halasa, T., K. Huijps, O. Østerås, and H. Hogeveen. 2007. Economic 
effects of bovine mastitis and mastitis management: A review. 
Vet. Q.  29:18–31.
Halasa, T., M. Nielen, R. B. M. Huirne, and H. Hogeveen. 2009. Sto-
chastic bio-economic model of bovine intramammary infection. 
Livest. Sci.  124:295–305.
Heikkilä, A.-M., J. I. Nousiainen, and S. Pyörälä. 2012. Costs of clini-
cal mastitis with special reference to premature culling.  J. Dairy 
Sci.  95:139–150.
Hogan, J. S., R. J. Harmon, B. E. Langlois, R. W. Hemken, and W. 
L. Crist. 1984. Efficacy of an iodine backflush for preventing new 
intramammary infections.  J. Dairy Sci.  67:1850–1859.
Huijps, K., T. J. Lam, and H. Hogeveen. 2008. Costs of mastitis: Facts 
and perception.  J. Dairy Res.  75:113–120.
Keefe, G. 2012. Update on control of Staphylococcus aureus and Strep-
tococcus agalactiae for management of mastitis.  Vet. Clin. North 
Am. Food Anim. Pract.  28:203–216.
Kossaibati, M. A., and R. J. Esslemont. 2000. The cost of clinical mas-
titis in UK dairy herds.  Cattle Pract.  8:323–327.
Lam, T. J. G. M., M. C. M. Dejong, Y. H. Schukken, and A. Brand. 
1996. Mathematical modeling to estimate efficacy of postmilking 
teat disinfection in split-udder trials of dairy cows.  J. Dairy Sci. 
79:62–70.
Lam, T. J., J. H. van Vliet, Y. H. Schukken, F. J. Grommers, A. van 
Velden-Russcher, H. W. Barkema, and A. Brand. 1997. The effect 
of discontinuation of postmilking teat disinfection in low somatic 
cell count herds. II. Dynamics of intramammary infections.  Vet. 
Q.  19:47–53.
Lunn, D. J., A. Thomas, N. Best, and D. Spiegelhalter. 2000. Win-
BUGS—A Bayesian modelling framework: Concepts, structure, 
and extensibility.  Stat. Comput.  10:325–337.
Mein, G. A. 2012. The role of the milking machine in mastitis control. 
Vet. Clin. North Am. Food Anim. Pract.  28:307–320.
Middleton, J. R., L. K. Fox, and T. H. Smith. 2001. Management 
strategies to decrease the prevalence of mastitis caused by one 
strain of Staphylococcus aureus in a dairy herd.  J. Am. Vet. Med. 
Assoc.  218:1615–1618.
O’Brien, B. J., M. F. Drummond, R. J. Labelle, and A. Willan. 1994. 
In search of power and significance: Issues in the design and analy-
sis of stochastic cost-effectiveness studies in health care.  Med. 
Care  32:150–163.
Olde Riekerink, R. G. M., H. W. Barkema, D. T. Scholl, D. E. Poole, 
and D. F. Kelton. 2010. Management practices associated with the 
bulk-milk prevalence of Staphylococcus aureus in Canadian dairy 
farms.  Prev. Vet. Med.  97:20–28.
R Development Core Team. 2012. R: A Language and Environment for 
Statistical Computing. R Foundation for Statistical Computing, 
Vienna, Austria.
Rodrigues, A. C. O., D. Z. Caraviello, and P. L. Ruegg. 2005. Manage-
ment of Wisconsin dairy herds enrolled in milk quality teams.  J. 
Dairy Sci.  88:2660–2671.
Smith, T. W., R. J. Eberhart, S. B. Spencer, E. M. Kesler, G. L. Har-
grove, R. W. Wilson, and C. W. Heald. 1985. Effect of automatic 
backflushing on number of new intramammary infections, bacteria 
on teatcup liners, and milk iodine.  J. Dairy Sci.  68:424–432.
Steeneveld, W., T. van Werven, H. W. Barkema, and H. Hogeveen. 
2011. Cow-specific treatment of clinical mastitis: An economic ap-
proach.  J. Dairy Sci.  94:174–188.
Swinkels, J. M., H. Hogeveen, and R. N. Zadoks. 2005a. A partial 
budget model to estimate economic benefits of lactational treat-
ment of subclinical Staphylococcus aureus mastitis.  J. Dairy Sci. 
88:4273–4287.
Swinkels, J. M., J. G. Rooijendijk, R. N. Zadoks, and H. Hogeveen. 
2005b. Use of partial budgeting to determine the economic benefits 
of antibiotic treatment of chronic subclinical mastitis caused by 
Streptococcus uberis or Streptococcus dysgalactiae.  J. Dairy Res. 
72:75–85.
Todhunter, D. A., K. L. Smith, and J. S. Hogan. 1995. Environmental 
streptococcal intramammary infections of the bovine mammary 
gland.  J. Dairy Sci.  78:2366–2374.
van den Borne, B. H. P., T. Halasa, G. van Schaik, H. Hogeveen, and 
M. Nielen. 2010. Bioeconomic modeling of lactational antimicro-
bial treatment of new bovine subclinical intramammary infections 
caused by contagious pathogens.  J. Dairy Sci.  93:4034–4044.
Wilson, D. J., R. N. Gonzalez, and P. M. Sears. 1995. Segregation or 
use of separate milking units for cows infected with Staphylococcus 
aureus: Effects on prevalence of infection and bulk tank somatic 
cell count.  J. Dairy Sci.  78:2083–2085.
Zadoks, R. N., H. G. Allore, H. W. Barkema, O. C. Sampimon, Y. 
T. Gröhn, and Y. H. Schukken. 2001. Analysis of an outbreak of 
Streptococcus uberis mastitis.  J. Dairy Sci.  84:590–599.
Zadoks, R. N., H. G. Allore, T. J. Hagenaars, H. W. Barkema, and 
Y. H. Schukken. 2002. A mathematical model of Staphylococcus 
aureus control in dairy herds.  Epidemiol. Infect.  129:397–416.
Zadoks, R. N., B. E. Gillespie, H. W. Barkema, O. C. Sampimon, S. 
P. Oliver, and Y. H. Schukken. 2003. Clinical, epidemiological and 
molecular characteristics of Streptococcus uberis infections in dairy 
herds.  Epidemiol. Infect.  130:335–349.
Zadoks, R. N., and Y. H. Schukken. 2006. Use of molecular epidemi-
ology in veterinary practice.  Vet. Clin. North Am. Food Anim. 
Pract.  22:229–261.
Zecconi, A., R. Piccinini, and L. K. Fox. 2003. Epidemiologic study 
of intramammary infections with Staphylococcus aureus during a 
control program in nine commercial dairy herds.  J. Am. Vet. Med. 
Assoc.  223:684–688.
